Varenicline enhances oxidized LDL uptake by increasing expression of LOX-1 and CD36 scavenger receptors through α7 nAChR in macrophages

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Douglas E. Jorenby · JAMA · 2006 · 1.7K citations

Medicine, Pharmacology, Pharmacotherapy +17

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

David Gonzales · JAMA · 2006 · 1.4K citations

Medicine, Pharmacology, Pharmacotherapy +17

CD36 is a receptor for oxidized low density lipoprotein

Gerda Endemann, Lawrence W. Stanton, Kelley S. Madden et al. · Journal of Biological Chemistry · 1993 · 1.3K citations · Full text

Life Sciences, Cell Biology, Immunology +17

Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary.

PubMed · 2008 · 520 citations

Public Health, Public Health Practice, Behavioral Health +11

Antisense to LOX-1 Inhibits Oxidized LDL–Mediated Upregulation of Monocyte Chemoattractant Protein-1 and Monocyte Adhesion to Human Coronary Artery Endothelial Cells

Dayuan Li, Jawahar L. Mehta · Circulation · 2000 · 420 citations · Full text

Life Sciences, Immunology, Cell Signaling +16